For research and educational purposes only. Not medical advice.

SR9009 Reference

Educational, not medical advice reference for SR9009: SARM, Fat Loss; regulatory status, evidence posture, source review, and schedule notes. Also known as S…

Reference summary

Published work is preclinical, focused on REV-ERBα agonism and circadian / metabolic phenotypes in rodents. Oral bioavailability of SR9009 is poor; community oral use likely produces little systemic exposure.

Categories

SARM, Fat Loss

Aliases

Stenabolic, REV-ERBα agonist, Non-SARM

Evidence posture

preclinical — Not a SARM — REV-ERBα agonist. Oral bioavailability is poor; community framing as an exercise mimetic outruns the published evidence. WADA-prohibited under category S4.5 hormone and metabolic modulators at all times. FDA enforcement attention.

Regulatory status

No FDA-approved SR9009 drug label. WADA prohibits SR9009 under category S4.5 hormone and metabolic modulators at all times. FDA enforcement against SARMs sellers applies even though SR9009 is technically a REV-ERBα agonist, not a SARM. Oral bioavailability of SR9009 is poor in published rodent literature.

Content review status

research reference

Selected public sources

• FDA consumer update: SARMs are not FDA-approved and cannot be legally marketed as dietary supplements
• WADA prohibited list: GW-501516 and SR9009-type agents are category S4.5 metabolic modulators prohibited at all times
• PubMed search: SR9009 (stenabolic) REV-ERBα agonist literature